Drug intelligence / Profile preview

AERO-002

Development stage: Phase 1
Lead developer: AeroRx Therapeutics
Administration: Inhalation

Overview

AERO-002 is an investigational drug and an active component in the combination bronchodilator product AERO-007, being developed for inhalation therapy. It is being studied for its pharmacokinetic profile and bronchodilator effects, particularly in the context of chronic obstructive pulmonary disease (COPD). The specific mechanism of action and molecular target for AERO-002 have not been disclosed publicly. Clinical studies are ongoing to determine its safety, tolerability, and efficacy as part of a nebulized maintenance treatment for COPD[5].

Beyond the preview

Go deeper on AERO-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AERO-002.

Explore the full profile